Tritoqualine is used as a histidine decarboxylase inhibitor. IC50 & Target: histidine decarboxylase^[1] In Vitro: The effect of Tritoqualine (TRQ) on the CCl₄-induced enzyme leakage is investigated by pretreatment of rats with Tritoqualine (200 mg/kg/day, p.o., 7 days). The ratio of lactate dehydrogenase (LDH) release from the cells of Tritoqualine-pretreated rats is significantly less than that in control rats. The rate of malondialdehyde (MDA) production is accelerated after the addition of 7.8 mM CCl₄. Tritoqualine reduces its rate in a dose dependent manner, and it completely prevents CCl₄-stimulated lipid peroxidation at a concentration of 33 μM^[2]. In Vivo: A single administration of CCl₄ (0.75 mL/kg, p.o.) causes a five-fold increase of in vivo lipid peroxidation in the liver. In contrast, a reduction of 37% in the lipid peroxidation is obtained by Tritoqualine (100 mg/kg) pretreatment for 14 days prior to CCl₄ treatment. A 63% reduction is observed in vitamin E (25 mg/kg) pretreated rats^[2].